Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Dynavax initiates combination cancer trial
The trial is designed to identify the optimum dose and to yield safety and tolerability data for escalating doses of a Dynavax TLR9 agonist administered with irinotecan and
The trial is designed to identify the optimum dose and to yield safety and tolerability data for escalating doses of a Dynavax TLR9 agonist administered with irinotecan and
This phase II trial will compare two doses of epinastine nasal spray to placebo. The trial will be conducted during the mountain cedar pollen season, which typically begins
In the study, type 2 diabetes patients not currently treated with anti-diabetic medications and receiving Acomplia significantly lowered their HbA1c blood sugar levels by 0.8% from a baseline
Isis said the unnamed compound takes advantage of its expertise in nucleic acid therapeutics. The company's research is focused exclusively on the therapeutic target, RNA and focuses on
Indicated for the temporary relief of itchy eyes, Alaway will be marketed over-the-counter and includes a prescription strength active ingredient. According to Alimera unlike over-the-counter anti-itch eye drop
Following FDA review, Lexicon intends to initiate a phase I clinical trial of LX1031 to assess the compound's safety, tolerability and pharmacokinetics. In preclinical studies, LX1031 has demonstrated
This phase IIa trial is designed to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of PRX-03140 administered orally once-daily for 14 days in patients with mild Alzheimer's disease
Patients treated with Lunesta demonstrated statistically significant improvement in measures of onset of sleep time spent awake and total sleep time. Secondary measures of sleep quality, depth of
The application is designed to permit initial clinical testing of Tripep's proprietary DNA vaccine, ChronVac-C, administered using Inovio's MedPulser DNA Delivery System. This combination is designed to activate
Chronic lymphocytic leukemia is the most common hematologic malignancy in the western hemisphere and remains incurable, said the researchers. While several phase II studies have demonstrated improved clinical